revenue outlook

Affirm’s Rollercoaster: Profit Milestone, Insider Sell-Off & Big BNPL Bets – What’s Next for AFRM?

AFRM Stock Today (Nov 6, 2025): Affirm Jumps After Q1 FY26 Beat, Extends Amazon Deal, Sets Q2 Revenue Outlook

Published: November 6, 2025 Affirm Holdings (NASDAQ: AFRM) surged in after-hours trading on Thursday after posting stronger‑than‑expected fiscal Q1 2026 results, raising the near‑term outlook and disclosing a multi‑year extension of its U.S. agreement with Amazon. Shares traded around the

6 November 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

What happened today Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the

6 November 2025

Biotechnology · Earnings Reports · Healthcare Industry · Pharmaceuticals · Stock Market